Concomitant cannabis abuse/dependence in patients treated with opioids for non-cancer pain

American Journal on Addictions

Volumn 24, Issue 6, 2015, Pages 538-545

  Hefner, Kathryn ^a,b   Sofuoglu, Mehmet ^a,b   Rosenheck, Robert ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; OPIATE; PSYCHOTROPIC AGENT; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; CHRONIC PAIN; CONCOMITANT CANNABIS USE DISORDER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAIN ASSESSMENT; POPULATION; PRESCRIPTION; PSYCHIATRIC TREATMENT; SUBSTANCE USE; VETERANS HEALTH; AGED; MARIJUANA ABUSE; PAIN; UNITED STATES;

ADULT; AGED; ANALGESICS, OPIOID; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PAIN; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84940447604     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12260     Document Type: Article

References (35)

1. Substance Abuse and Mental Health Services Administration. Results from the 2010 National survey on drug use and health: Summary of National findings and detailed tables. Rockville: Department of Health and Human Services; 2011.
2. Morasco BJ, Turk D C, Donovan D M, et al. Risk for prescription opioid misuse among patients with a history of substance use disorder. Drug Alcohol Depend. 2013;127:193-199.
3. Abrams DI, Couey P, Shade SB, et al. Cannabinoid-opioid interactions in chronic pain. Clin Pharmacol Ther. 2011;90:844-854.
4. Reisfield GM, Wasan A D, Jamison R N. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: A review of the extant literature. Pain Med. 2009;10:1434-1441.
5. Reisfield G M. Medical cannabis and chronic opioid therapy. J Pain Palliat Care Pharmacother. 2010;24:356-361.
6. Michna E, Jamison R N, Pham L-D, et al. Urine toxicology screening among chronic pain patients on opioid therapy: Frequency and predictability of abnormal findings. Clin J Pain. 2007;23:173-179.
7. Barry DT, Sofuoglu M, Kerns RD, et al. Prevalence and correlates of coprescribing psychotropic medications with long-term opioid use nationally in the Veterans Health Administration. Psychiatry Research. 2015;227:324-332.
8. Pesce A, West C, Rosenthal M, et al. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician. 2010;13:283-287.
9. Haller DL, Acosta MC. Characteristics of pain patients with opioid-use disorder. Psychosomatics. 2010;51:257-266.
10. Manchikanti L, Cash K, Damron K, et al. Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician. 2006a;9:215-225.
11. Morasco B J, Gritzner S, Lewis L, et al. Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. PAIN1. 2011;152:488-497.
12. Huffman K L, Shella E R, Sweis G, et al. Nonopioid substance use disorders and opioid dose Predict therapeutic opioid addiction. J Pain. 2015;16:126-134.
13. Manchikanti L, Manchukonda R, Pampati V, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006b;9:123-129.
14. FlemingMF, Balousek S L, Klessig C L, et al. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8:573-582.
15. Stinson F S, Ruan W J, Pickering R, et al. Cannabis use disorders in the USA: Prevalence, correlates and co-morbidity. Psychol Med. 2006;10:1447-1460.
16. Finney J W, Willenbring M L, Moos R H. Improving the quality of VA care for patients with substance-use disorders: The quality enhancement research initiative (QUERI) substance abuse module. Med Care. 2000;38: I105-I113.
17. Bonn-Miller M O, Harris S, Trafton J A. Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv. 2012;9:404-416.
18. Kandel DB, Yamaguchi K, Chen K. Stages of progression in drug involvement from adolescence to adulthood: Further evidence for the gateway theory. J Stud Alcohol. 1992;53:447-457.
19. Dobscha S K, Corson K, Flores J A, et al. Veterans affairs primary care clinicians' attitudes toward chronic pain and correlates of opioid prescribing rates. Pain Med. 2008;9:564-571.
20. Ware M A, Doyle C R, Woods R, et al. Cannabis use for chronic noncancer pain: Results of a prospective survey. Pain. 2003;102:211-216.
21. Petrakis IL, Sofuoglu M, Rosenheck R. VA Patients with high numbers of opioid prescriptions: A national study of sociodemographic and diagnostic characteristics, health service, and psychotropic medication use. Addict Disord Treat. Advance online publication 2015; DOI: 10.1097/ADT.0000000000000058.
22. Charlson M E, Pompei P, Ales K L, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373-383.
23. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2 edition). Hillsdale, N.J: Routledge; 1988.
24. Scavone J L, Sterling R C, Weinstein S P, et al. Impact of cannabis use during stabilization on methadone maintenance treatment. Am J Addict. 2013;22:344-351.
25. Scavone J L, Sterling R C, Van Bockstaele E J. Cannabinoid and opioid interactions: Implications for opiate dependence and withdrawal. Neuroscience. 2013;248:637-654.
26. Cichewicz D L, McCarthy E A. Antinociceptive ssynergy between D9-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther. 2003;304:1010-1015.
27. Roberts J D, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol. 2006;530:54-58.
28. Ellgren M, Spano S M, Hurd Y L. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology. 2007;32:607-615.
29. Spano M S, Fadda P, Fratta W, et al. Cannabinoid-opioid interactions in drug discrimination and self-administration: Effect of maternal, postnatal, adolescent and adult exposure to the drugs. Curr Drug Targets. 2010;11:450-461.
30. Cerda M, Wall M, Keyes KM, et al. Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012;120:22-27.
31. HayesMJ, BrownMS. Legalization of medical marijuana and incidence of opioid mortality. JAMA Intern Med. 2014;174:1673-1674.
32. Volkow N D, Baler R D, Compton W M, et al. Adverse health effects of marijuana use. New Engl J Med. 2014;370:2219-2227.
33. Dart R C, Surratt H L, Cicero T J, et al. Trends in opioid analgesic abuse and mortality in the United States. New Engl J Med. 2015;372:241-248.
34. Clark D B, Bukstein O G, Smith M G, et al. Identifying anxiety disorders in adolescents hospitalized for alcohol abuse or dependence. Psychiatr Serv. 1995;46:618-620.
35. Rincon H G, Granados M, Unutzer J, et al. Prevalence, detection and treatment of anxiety, depression, and delirium in the adult critical care unit. Psychosomatics. 2001;42:391-396.